Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotech focused on PLK1 inhibition in cancer, will participate in the Jefferies Global Healthcare Conference from June 2-4, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cardiff Oncology (Nasdaq: CRDF), a clinical-stage biotech focused on PLK1 inhibition in cancer, will participate in the Jefferies Global Healthcare Conference from June 2-4, 2026. Management will join a fireside chat and 1x1 investor meetings.
The fireside chat with President and CEO Mani Mohindru, PhD is scheduled for June 4, 2026, from 10:30-11:00 AM ET. A live webcast and replay will be available via the Events section of the Cardiff Oncology website.
Details
News Market Reaction – CRDF
On Jun 2, the first trading day after this news, CRDF closed 2.03% above the previous close.
Data tracked by StockTitan Argus for the Jun 2 session.
Key Figures
- Conference dates
- June 2-4, 2026
- Jefferies Global Healthcare Conference schedule
- Presentation date
- 06/04/2026
- Cardiff Oncology fireside chat date
- Presentation time
- 10:30-11:00 AM ET
- Duration of Jefferies conference fireside chat
- Price change
- 3.26%
- Move on day of conference participation announcement
Historical Context
-
Announced investor webcast to review updated Phase 2 CRDF-004 data.
-
Reported Q1 2026 results, positive Phase 2 data, and cash runway into Q1 2027.
-
Announced 400,000 stock options inducement grant for new COO.
-
Planned key opinion leader webinar on single-agent onvansertib activity in CMML.
-
Planned updated Phase 2 onvansertib data presentation at ASCO 2026.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
1x1 investor meetings financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies Global Healthcare Conference on June 2-4, 2026.
Details of the presentation can be found below.
Format: Fireside Chat
Presenter: Mani Mohindru, PhD (President and CEO)
Date: 06/04/2026
Time: 10:30 -11:00 AM ET
Interested parties can register for and access the live webcast for the conference by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the presentation.
About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.
For more information, please visit https://www.cardiffoncology.com.
Investor Contact:
Candice Masse
Astr Partners
candice.masse@astrpartners.com
Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.